View More View Less
  • 1 Kaposi Mór Teaching Hospital Internal Medicine Department Tallian Gyula u. 20–32 H-7400 Kaposvár Hungary
  • | 2 Faculty of Medicine, Semmelweis University 1st Institute of Pathology Budapest Hungary
Restricted access

Introduction: Chronic myeloid leukaemia is a malignant clonal alteration of the pluripotent haemopoietic stem cell. The genetic hallmarks of the disease are the t(9,22) (Philadelphia chromosome), registered by conventional cytogenetics in more than 90% of all chronic myeloid leukaemia cases and the active tyrosine kinase protein encoded by bcr-abl fusion gene. The constitutively active tyrosine kinase is currently accepted to be the cause of chronic myeloid leukaemia. The introduction of imatinib has considerably changed the treatment of chronic myeloid leukaemia. Prior studies demonstrated high rates of cytogenetic responses in all phases of the disease. Methods: The authors evaluated the cytogenetic and molecular responses of 20 chronic phase chronic myeloid leukaemia patients who were consecutively admitted to their center. 13 of them were primarily treated with imatinib, and the other 7 were heavily pretreated with interferon alfa, cytarabine, all-trans-retinoic acid. Hydroxyurea pretreatment was routinely introduced in all patients until complete haematologic remission. Peripheral blood samples were collected in every 3rd month for quantitative real-time polymerase chain reaction, and bone marrow aspirate in every 6th month for conventional cytogenetics, respectively. Results: Haematologic remission could be achieved with hydroxyurea pretreatment in each patient. Complete cytogenetic remisson at the 6th month and major molecular response at the 12th month were observed in each patient. Conclusions: Imatinib treatment caused complete cytogenetic response and major molecular response in each chronic phase chronic myeloid leukaemia patient in our group. Hydroxyurea might have some effect on the rapid and deep cytogenetic and molecular responses, observed in the primary imatinib treated group.

  • Colombat, M., Fort, M. P., Chollet, C. et al.: Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica, 2006, 91 , 162–168.

    Chollet C. , 'Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment ' (2006 ) 91 Haematologica : 162 -168.

    • Search Google Scholar
  • Kajtár, B., Méhes, G., Kereskai, L. et al.: Cytogenetic and molecular monitoring of chronic myeloid leukemia. Orv. Hetil., 2006, 147 , 963–970.

    Kereskai L. , 'Cytogenetic and molecular monitoring of chronic myeloid leukemia ' (2006 ) 147 Orv. Hetil. : 963 -970.

    • Search Google Scholar
  • Radich, J. P., Dai, H., Mao, M. et al.: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA, 2006, 103 , 2794–2799.

    Mao M. , 'Gene expression changes associated with progression and response in chronic myeloid leukemia ' (2006 ) 103 Proc. Natl. Acad. Sci. USA : 2794 -2799.

    • Search Google Scholar
  • Cortes, J., Talpaz, M., O’Brien, S. et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res., 2005, 11 , 3425–3432.

    O’Brien S. , 'Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate ' (2005 ) 11 Clin. Cancer Res. : 3425 -3432.

    • Search Google Scholar
  • Deininger, M., Buchdunger, E., Druker, B. J. et al: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105 , 2640–2653.

    Druker B. J. , 'The development of imatinib as a therapeutic agent for chronic myeloid leukemia ' (2005 ) 105 Blood : 2640 -2653.

    • Search Google Scholar
  • Kantarjian, H., O’Brien, S., Cortes, J. et al.: Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-failure and in late CML-CP, comparison with historical controls. Clin. Cancer Res., 2004, 10 , 68–75.

    Cortes J. , 'Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-failure and in late CML-CP, comparison with historical controls ' (2004 ) 10 Clin. Cancer Res. : 68 -75.

    • Search Google Scholar
  • Baccarani, M., Saglio, G., Goldman, J. et al.: Evolving concepts in the management of chronic myeloid leukemia: recommendation from an expert panel on behalf of the European Leukemia Net. Blood, 2006, 108 , 1809–1820.

    Goldman J. , 'Evolving concepts in the management of chronic myeloid leukemia: recommendation from an expert panel on behalf of the European Leukemia Net ' (2006 ) 108 Blood : 1809 -1820.

    • Search Google Scholar
  • Egyed, M., Kollár, B., Keller, E. et al.: Effect of retinoic acid treatment on cytogenetic remission of first chronic phase of chronic myeloid leukemia treated with interferon. Orv. Hetil., 2001, 142 , 2421–2425.

    Keller E. , 'Effect of retinoic acid treatment on cytogenetic remission of first chronic phase of chronic myeloid leukemia treated with interferon ' (2001 ) 142 Orv. Hetil. : 2421 -2425.

    • Search Google Scholar
  • Egyed, M., Kollár, B., Keller, E. et al.: Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia. Acta Haematol., 2003, 109 , 84–89.

    Keller E. , 'Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia ' (2003 ) 109 Acta Haematol. : 84 -89.

    • Search Google Scholar
  • Muus, P., Egyed, M., Beksac, B. et al.: All-Trans Retinoic Acid (ATRA) in addition to r-interferon alpha in CML in first chronic phase. A feasibility study by EORTC-LCG.; Blood, 1999, 9, Suppl. abst. 4452.

  • Roche-Lestienne, C., Mahon, F., Guilhot, J. et al.: First Overall Molecular Response of the Randomized French SPIRIT study on behalf of the Fi-LMC group.; Blood, 2006, 108 , abstr. 2151.

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)